Lupin launches Bumetanide Injection USP in US
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Modernization and supply chain diversity drive new growth
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Subscribe To Our Newsletter & Stay Updated